- Table View
- List View
Nova Chemical Corp.
by Scott P. MasonA diversified chemical company must decide whether to sell its basic chemicals division and expand the specialty chemicals division.
Novartis: A Transformative Deal
by David J. Collis Ashley HartmanWhen Joe Jimenez became CEO of Swiss-based Novartis in 2010 replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and structured it into sixteen distinct business units ranging from animal health to oncology while "actively fostering competition between those divisions for resources." Shortly after assuming his position, Jimenez initiated a strategic review that sought to concentrate the portfolio on businesses where Novartis could be at global scale in attractive markets. Rather than following competitors, like Pfizer, in a single mega-acquisition, Jimenez and his M&A team decided to achieve this goal through targeted transactions, or "precision M&A". By 2014 after examining twenty or so possible deals, the company was in the process of negotiating a multi-billion dollar asset swap with Glaxo-Smith Kline (GSK) that was unprecedented in the pharma industry. Although Novartis would improve its position in oncology by acquiring GSK's promising drug portfolio, it had to sell its vaccines and animal health businesses, while giving up control of the over-the-counter (OTC) business. Jimenez and his team knew the offer was "all-or-nothing" and struggled over whether to accept it, or reject it and move in another direction.
Novartis: Leading a Global Enterprise
by Carin-Isabel Knoop Krishna G. Palepu William W. GeorgeNovartis, the world's leading healthcare company, was formed in 1996 out of a merger of two very different, mid-tier Switzerland-based pharma companies. The case traces the company's evolution over the past 17 years, as it transformed into a truly global enterprise with 127,000 employees of 153 nationalities in 140 countries generating $56.7 billion in 2012 revenues and $9.6 billion in net income, making the firm one of the world's largest and most profitable companies. CEO since 2010, Joe Jimenez had taken over from one of the merger's architects and visionary legacy CEO Daniel Vasella. He recognized that the global health care environment would create severe challenges for Novartis in the years ahead and that Novartis needed to make sure it had the right strategy, structure, talent and spirit to live up to its ambitions.
Novartis (A): Being a Global Leader
by Carin-Isabel Knoop Srikant M. DatarFor the Novartis leaders, the decision to "use stretch budgets again next year" highlights the tension between candor and empowerment and command-and-control, between the new and the old, between high performance and business as usual, between Ciba and Sandoz. Management must decide what kind of company and culture they want to build.
Novartis AG: Science-Based Business
by Courtney Purrington H. Kent BowenNovartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007, corporate R&D spending was $6.43B, or almost 17% of net sales. Novartis executive leaders believe in scientific progress and that large-scale investments in science will therefore result in long-term pay-offs in terms of profits and discoveries that benefit mankind. Novartis' business strategy is closely tied to its research strategy, which emphasizes extensive internal discovery and development capabilities leading to organic growth along with explicit external alliances and collaborations to supplement its core capabilities. Like its competitors, Novartis faces many challenges in terms of moving research from the bench to the bedside. Five years after undertaking the restructuring of the discovery research organization, CEO Daniel Vasella is pleased with its progress, including many more development projects in the pipeline and new molecular entities. Nevertheless, the company faces a number of challenges, including generic drugs, patent infringements in developing countries, and pricing pressure from governments and health insurers in the United States. Given these challenges, Novartis must decide how much to spend on R&D overall, how to arrive at the right mix between organic growth and external collaboration and in-licensing, and how to measure success when it takes so many years to develop and launch a successful drug.
The Novartis Malaria Initiative
by Emilie Billaud Vincent Dessain Michael ChuThe Novartis Malaria Initiative was designed, as a result of a precedent-setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria-"at no profit"-for public health systems. What had begun as an exemplary act of corporate responsibility had succeeded beyond any expectations. In 2012, for the second year in a row, Novartis had manufactured and distributed over 100 million units of the anti-malarial drug Coartem . But with the significantly increased volumes came increased costs, bringing into question the sustainability of the program. In 2013, Dr. Linus Igwemezie, executive vice president and head of the Novartis Malaria Initiative, reflected on the evolution of the program and the way forward. His goal was to expand access to Coartem in the private sector through a low-margin, high-volume social business model to eventually enable the Malaria Initiative to break even and become financially sustainable. Was this the right strategy?
Novartis Pharma: The Business Unit Model
by Carin-Isabel Knoop Srikant M. Datar Cate ReavisIn June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing). The new organization created a matrix structure and new roles and responsibilities for heads of business functions, CEOs of new business units, and country managers operating in over 100 countries.
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
by Aldo Sesia Gautam Mukunda Thomas J. DelongThis (B) case describes the actions Andre Wyss, President of Novartis Pharmaceuticals Corp., took in early 2012 to transform the company's General Medicines group and build its speciality medications marketing the selling capabilities in the face of falling revenues and an imminent workforce reduction. Rather than downsize the organization quickly to save costs, Wyss and his team took a different approach. They told the organization's employees that there would be a significant workforce reduction but it would not occur for several months. In the meantime, Wyss asked the employees to help build the new capabilities and put processes in place to support the move into specialty medications. It was a bold decision and defied convention.
Novartis' Sandoz: Between Generics and Pharma
by Carin-Isabel Knoop Krishna G. PalepuSandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?
Novartis: A Transformative Deal
by David J. Collis Ashley HartmanWhen Joe Jimenez became CEO of Swiss-based Novartis in 2010 replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and structured it into sixteen distinct business units ranging from animal health to oncology while "actively fostering competition between those divisions for resources." Shortly after assuming his position, Jimenez initiated a strategic review that sought to concentrate the portfolio on businesses where Novartis could be at global scale in attractive markets. Rather than following competitors, like Pfizer, in a single mega-acquisition, Jimenez and his M&A team decided to achieve this goal through targeted transactions, or "precision M&A". By 2014 after examining twenty or so possible deals, the company was in the process of negotiating a multi-billion dollar asset swap with Glaxo-Smith Kline (GSK) that was unprecedented in the pharma industry. Although Novartis would improve its position in oncology by acquiring GSK's promising drug portfolio, it had to sell its vaccines and animal health businesses, while giving up control of the over-the-counter (OTC) business. Jimenez and his team knew the offer was "all-or-nothing" and struggled over whether to accept it, or reject it and move in another direction.
NovaStar Financial: A Short Seller's Battle
by Amy Kaser Suraj SrinivasanThe NovaStar case describes the challenges faced by short seller Marc Cohodes of hedge fund Rocker Partners as he tried to expose what he thought was widespread fraud in mortgage lender NovaStar Financial. The case is set in the time period from 2001 to 2007 and tracks the growth of the subprime industry and its collapse leading to the financial crisis. The case describes the business model of NovaStar, a leading subprime mortgage lending company, and its accounting practices with a focus on the key risks and opportunities facing the company. The case requires students to put themselves in the shoes of Marc Cohodes in order to understand the business model and accounting numbers and to identify if the financial performance is a good representation of the true economic performance. In particular, students learn accounting concepts related to securitization, gain on sale accounting, valuation of available for sale securities, and analyzing the statement of cash flows. The case also allows students to understand the roles and incentives of various capital market participants such as sell-side analysts, the media, auditors, and the Securities and Exchange Commission (SEC).
Novel Developments for Sustainable Hydropower
by Peter Rutschmann Eleftheria Kampa Christian Wolter Ismail Albayrak Laurent David Ulli Stoltz Martin SchlettererThis open access book presents (selected) new and innovative developments for sustainable and fish-friendly hydropower. It offers unique insights into the challenges, practices and policies of hydropower developments across 8 European countries, providing examples from on-site studies and European-wide analyses. The case studies throughout the book are practical “real-world” examples, which are intended to serve as inspiration for anyone who would like to know more about how solutions for more sustainable hydropower production can be designed and implemented. Hydropower is an important renewable energy source, which, however, can also impact aquatic ecosystems, fish populations and hydro-morphology. EU and national water, environmental and energy legislation strive for sustainable energy and water resource management as well as the protection of important habitats and species. These have an effect on the requirements and decision making processes for hydropower planning, commissioning and operation. With a high variety of measures existing and site-specific conditions as well as national and EU level legal requirements to consider, it can be difficult to determine, what issues to address and which measures to implement.
Novel Financial Applications of Machine Learning and Deep Learning: Algorithms, Product Modeling, and Applications (International Series in Operations Research & Management Science #336)
by Mohammad Zoynul Abedin Petr HajekThis book presents the state-of-the-art applications of machine learning in the finance domain with a focus on financial product modeling, which aims to advance the model performance and minimize risk and uncertainty. It provides both practical and managerial implications of financial and managerial decision support systems which capture a broad range of financial data traits. It also serves as a guide for the implementation of risk-adjusted financial product pricing systems, while adding a significant supplement to the financial literacy of the investigated study. The book covers advanced machine learning techniques, such as Support Vector Machine, Neural Networks, Random Forest, K-Nearest Neighbors, Extreme Learning Machine, Deep Learning Approaches, and their application to finance datasets. It also leverages real-world financial instances to practice business product modeling and data analysis. Software code, such as MATLAB, Python and/or R including datasets within a broad range of financial domain are included for more rigorous practice. The book primarily aims at providing graduate students and researchers with a roadmap for financial data analysis. It is also intended for a broad audience, including academics, professional financial analysts, and policy-makers who are involved in forecasting, modeling, trading, risk management, economics, credit risk, and portfolio management.
Novel Foods and Edible Insects in the European Union: An Interdisciplinary Analysis
by Lucia Scaffardi Giulia FormiciThis open access book proposes an in-depth study on a vast range of issues connected to the regulation of Novel Foods in the European Union, pursuing an interdisciplinary approach and thus providing a comprehensive picture of this complex topic. Particular attention is paid not only to the current EU legislative framework, its positive innovations, unsolved problems and limits, but also to food safety issues and the potential impact of Novel Foods on sustainability and food security. In addition, the book focuses on a particular category of Novel Foods: insects for human consumption. These products recently gained momentum after the first EU Commission authorisation of dried yellow mealworm (Tenebrio molitor) in 2021. The book contributes to the lively public debate following this long-awaited authorisation by examining the legal issues arising from the application of the Novel Foods Regulation to these peculiar new foods; the EFSA risk assessment evaluations; the consumers’ perceptions and potential future of insect-based products’ market in the EU. By providing such an extensive analysis, including recent developments and future prospects, the book represents a valuable tool for students and academics, but also institutions and public authorities, helping them understanding the various challenges related to Novel Foods and edible insects. Furthermore, it seeks to promote an informed debate in order to find innovative solutions to pressing problems concerning how to feed the world of tomorrow.
Novel Innovation Design for the Future of Health: Entrepreneurial Concepts for Patient Empowerment and Health Democratization
by Michael FriebeThis book highlights the reasons for an urgently needed revision of the current global healthcare setup, discusses the needed mindset for a future of health, and provides a comprehensive development toolset for disruption (and for the needed incremental innovations towards disruption).Today’s biomedical and health innovation related research in universities encourages activities that lead to incremental innovations with a relatively low risk of failure. The healthcare industry on the other hand provides tools and devices for established healthcare providers to improve the diagnosis and therapy/ treatment of the patients’ health problems. The patient is not in the center of healthcare provision however, and prevention and prediction are not core goals. The current health setup needs to be challenged and disrupted.Disruptions are coming from technologies or processes that lead to a significant (>10x) reduction in cost or price/ performance and that also come with new business models. The need for change, effects of exponential technologies, and the needed shift to prevention and to homecare for health democratization and patient empowerment will be discussed in detail in the first parts of the book. The subsequent sections address several innovation methods with a focus on a novel meta methodology named Purpose Launchpad Health. This is followed by a comprehensive discussion on health entrepreneurship activities and needs. The final section of the book addresses how to train students to become entrepreneurial health innovators, presenting successful curricula and examples of health incubation and accelerator setups. All of the innovation tools presented and used in this book are summarized in the final chapter to help the reader get started planning an entrepreneurial venture.Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments. Chapters are concise and enriched with key messages, learning objectives and real innovation examples to bridge theory and practice. This book aims to serve as a teaching base for health innovation design and to prepare for health-related entrepreneurial ventures.Readers with medical, biomedical, biotechnology, and health economics backgrounds - and anyone who wants to become a future oriented health innovator or who believes in disruptive approaches - will find this book a useful resource and teaching tool for developing validated products/ services and processes for the future of health.
Novel Measurement and Assessment Tools for Monitoring and Management of Land and Water Resources in Agricultural Landscapes of Central Asia
by Lothar Mueller Abdulla Saparov Gunnar LischeidThe book aims to initiate a sustainable use of land and water resources in Central Asia by the transfer of scientific methods. It deals with the most advanced methods worldwide for better monitoring and management of water and land resources. We offer an array of methods of measuring, assessing, forecasting, utilizing and controling processes in agricultural landscapes. These are laboratory and field measurement methods, methods of resource evaluation, functional mapping and risk assessment, and remote sensing methods for monitoring and modeling large areas. The book contains methods and results of data analysis and ecosystem modeling, of bioremediation of soil and water, field monitoring of soils, and methods and technologies for optimizing land use systems as well. The chapter authors are inventors and advocators of novel transferrable methods. The book starts with an analysis of the current state of water and land resources. Finally concrete proposals for the applicability of novel methods are given.
Novel Sustainable Alternative Approaches for the Textiles and Fashion Industry (Sustainable Textiles: Production, Processing, Manufacturing & Chemistry)
by Subramanian Senthilkannan MuthuEnvironmental impacts created by the textiles and fashion sector are well known and acknowledged by various stakeholders involved in the entire supply chain. The entire lifecycle of textile products creates various impacts to the environment and hence any attempts to alleviate the impacts are highly welcomed. The whole sector is keen to investigate novel sustainable alternatives in terms of raw materials, processes, approaches to make the entire textiles and fashion sector more sustainable. This broad title of novel sustainable alternatives can be split into three subtopics: novel raw material alternatives, novel process alternative and novel alternative approaches. This volume is dedicated to deal with the novel sustainable alternative approaches for the textiles and fashion industry.
Novel Technologies in Food Science
by Anna Mcelhatton Paulo José do Amaral SobralThe book covers novel technologies, including high pressure, antimicrobials, and electromagnetism, and their impact.
Novell: Open Source Software Strategy
by Robert D. AustinDescribes Novell's open source software strategy and the business environment in which it has arisen. Introduces open source software and strategies based on open source and offers opportunities to discuss IT strategy, IT management, and organizational change. One key issue is how to capture value via a strategy that leverages intellectual property that is in the public domain.
Novell (A): When an Activist Hedge Fund Came Calling on the Board
by Richard L. NolanNo corporation and its board of directors is immune to a disruptive shareholder activist attack. The Novell (A) and (B) cases take students through a shareholder activist attack and its aftermath -- a saga that spanned 5 years. The cases outline the activist playbook in conducting an attack, the board's response, and key decisions that must be made.
Novell (B): Board of Directors Aftermath of Hedge Fund Attack
by Richard L. NolanSupplement to case 916404. No corporation and its board of directors is immune to a disruptive shareholder activist attack. The Novell (A) and (B) cases take students through a shareholder activist attack and its aftermath-a saga that spanned 5 years. The cases outline the activist playbook in conducting an attack, the board's response, and key decisions that must be made.
Novelty: One Dimension of Adaptive Project Management
by Dov Dvir Aaron J. ShenharWith a new product, market research is less reliable and requirements are less clear. This chapter looks at the affects of project novelty on managerial behavior, marketing activities, and other tasks of project management.
Novo Industri
by Michael J. Enright Michael E. PorterDescribes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an early case in global strategy. The class can understand how Novo has competed internationally in the past, how that relates to industry structure, and how industry changes will alter the appropriate way of competing globally. Coalitions of alliances factor into the list of strategic alternatives.
Novo Nordisk: A Commitment to Sustainability
by Michael P. Krzus Robert G. EcclesThe case describes the early commitment of a European pharmaceutical company, Novo Nordisk, to integrated reporting. Novo Nordisk is one of the pioneers of integrated reporting and it emerged out of its commitment to a "Triple Bottom Line approach to managing the company." The case describes the company's "Blueprint for Change Programme" designed to facilitate stakeholder engagement and communicate how the company delivered value to business and society. The case also provides an investor perspective on the company's integrated reporting efforts and its plans for how to improve it in the future.